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Abstract
Background
Management practices of complicated skin and skin structure infections (cSSSI) were compared
between two areas with similar healthcare structure and low prevalence of antimicrobial resistance.
Methods
The high affinity to public health-care in the Nordic countries enabled population-based approach
used in this retrospective study. The study population (n=460) consisted of all adult residents from
Helsinki (Finland) and Gothenburg (Sweden) treated in hospital due to cSSSI during 2008 – 2011.
Results
The majority of patients in Helsinki (57%) visited more than one ward during their hospital stay
while in Gothenburg the majority of patients (85%) were treated in one ward only. Background and
disease characteristics were largely similar in both cities but patients in Helsinki were younger
[mean(SD) 59(18) versus 63(19) years, p=0.0117], and greater proportions had diabetes (50%
versus 32%, p<0.0001) and polymicrobial infections (34% versus 13%, p<0.0001). Patients in
Helsinki received antimicrobials with Gram-negative coverage (in initial therapy 96%) more
frequently than in Gothenburg (47%, p<0.0001), had more treatment modifications (mean 4.3
versus 2.7 antibiotic agents used per patient, p<0.0001), and longer median duration of
antimicrobial therapy (29 versus 12 days, p<0.0001) and median length of hospital stay (17 versus
11 days, p<0.0001).
Conclusions
This real-life study revealed remarkable differences in the management of cSSSI between the two
Nordic cities. Compared to mainly Infectious Disease Specialist guided treatment in Gothenburg,
the more frequent transfer from one ward to another in Helsinki was linked to longer antimicrobial
therapy and hospital stay and to more frequent changes in antimicrobial treatment.
Introduction
Skin and skin structure infections (SSSIs) are a common and a rapidly increasing reason for
hospitalization [1,2]. SSSI is generally considered as complicated (cSSSI) if it involves deep
subcutaneous tissues or needs surgery in addition to antimicrobial therapy [3]. SSSI can also be
classified as complicated if it affects a patient with significant underlying co-morbidities like
diabetes or peripheral vascular disease. Streptococci and Staphylococcus aureus are the most
common causative agents in SSSIs but in complicated cases Gram-negative rods and anaerobic
bacteria may also play a role [4–7].
There are many antimicrobial therapies available for SSSI and antibiotic treatments from penicillin
to broad-spectrum combinations have been recommended in guidelines [8–10]. A cohort study
suggested that inappropriately broad-spectrum antibiotics were used in the milder SSSIs and that
the most severe cSSSIs were treated with insufficient antimicrobial coverage [11]. Inappropriate
empirical antimicrobial therapy was also associated with longer length of stay and higher total
costs [12]. In addition to the variation in antimicrobial therapies used, notable variability in the
treatment duration of cSSSI has been reported [13–17].
Finland and Sweden are countries with a low prevalence of methicillin resistant Staphylococcus
aureus (MRSA, in 2011: Finland 2.8%, Sweden 0.8%) in contrast to many other European
countries [18,19]. Therefore, antibiotics with MRSA-coverage are not recommended for the
empirical treatment of SSSI in the national guidelines [20,21]. Yet, differences exist between the
national guidelines of Finland and Sweden, especially in the suggested duration of antimicrobial
treatment for uncomplicated erysipelas/cellulitis which is 14 – 21 days in Finland and 10 – 14 days
in Sweden [20,21].
Finland and Sweden share high affinity to public health care which enables comparison of
treatment practices in comprehensive populations of patients with cSSSI. In the primary analysis of
the study data [22], we observed great differences in the characteristics and treatment practises of
cSSSI between two Nordic cities, Helsinki in Finland and Gothenburg in Sweden. The aim of this
retrospective real-life study was to further evaluate the factors behind the differences between
countries may offer means to optimize the antimicrobial treatment and clinical management of
cSSSI.
Methods
The inclusion and exclusion criteria of this observational retrospective cohort study are described
in detail in the primary publication of this study [22]. The study population consisted of all adult
residents who were treated in hospital because of cSSSI during 2008 – 2011 from cities with nearly
equal size of population (Helsinki, Finland, population of 588 000 and the Gothenburg area,
Sweden, population 600 000). For patient case finding, first selection was made from hospital
databases by certain ICD10 diagnostic codes. Inclusion criteria to the final analysis population
were an infection requiring significant surgical intervention, affecting deeper soft tissue, developed
on a lower extremity in a subject with diabetes mellitus or peripheral vascular disease, or a major
abscess or infected ulcer. Patients also had to have at least one systemic sign of infection: body
temperature of > 38 or < 36°C, or white blood cell count of > 10,000/mm3 or < 4,000/mm³.
Infection was defined as health-care associated if the patient had been hospitalized or had
undergone invasive surgery within previous three months. Cellulitis/fasciitis was defined as no
abscess, diabetic foot/leg ulcer or peripheral vascular ulcer. The evaluation of clinical stability was
based on improvement of vital signs and decreased fever in addition to local signs of infection.
Treatment failure was defined as need for unplanned surgery, no improvement in clinical situation
after 5 days of treatment, or treatment failure registered in patient records by treating physician.
Data for evaluation of recurrences and mortality were collected 1-year post-cSSSI diagnosis.
To enable comparison between cities, patients treated in Helsinki City hospital were combined into
the clinic of Medicine and treatment at Home hospital (Helsinki) was regarded as home-based
care; but since the Home hospital had treatment facilities similar to in-patient treatment (e.g.
intravenous antibiotics), the treatment was included to the total length of hospital stay. Home-
based care included follow up of cure, wound care or other forms of nursing.
Categorical variables were summarized using counts and percentages. The Fischer´s exact test
and Cochran-Mantel-Haenszel statistics, controlling for age, were utilized in the statistical analyses
of categorical variables. Continuous variables were summarized using means, standard deviation,
median, first and third quartile, min and max values. For continuous variables, a two sample t-test
or the analysis of variance (ANOVA) were used to test for difference between two subgroups and if
assumption of normal distribution was violated, also Wilcoxon rank-sum test was used.
Results
Patient population and baseline characteristics
1164 patients in Helsinki and 2151 in Gothenburg with possible SSSI were identified by hospital
discharge ICD10-codes, of which 219 and 241 patients, respectively, met the inclusion criteria for
cSSSI. In Helsinki, 191 patients were included from Helsinki University Central Hospital and 28
from Helsinki City Hospital; in Gothenburg all patients were from Sahlgrenska University Hospital.
The average annual incidence of cSSSI within the study period was 9/100,000 in Helsinki and
10/100,000 in Gothenburg. Compared to patients in Gothenburg, patients in Helsinki were slightly
younger and had greater frequency of chronic renal failure, diabetes or a prior hospitalization
(Table 1). Patients in Gothenburg were treated statistically significantly more often with antibiotics
before their infection met the cSSSI criteria (Table 1).
Statistically significant differences were not found between Helsinki and Gothenburg in the
proportion of patients with abnormal white blood cell count, in the peak C-reactive protein level, in
the occurrence of septic shock or in the need for blood pressure support (Table 2). However, blood
culture-positive infections were more common in Helsinki (18 % of patients) than in Gothenburg
(9.1 % of patients, p = 0.0102). On average, the diagnosis of cSSSI was made later in Gothenburg
in comparison to Helsinki although in both cities half of the patients were diagnosed between 2 to 7
days after the symptoms had started (Table 2). Cellulitis and abscess were the main diagnoses,
with similar proportions in both cities, but postsurgical wound infections were more common in
Helsinki, whereas infected ulcers related to peripheral vascular disease or pressure were more
common in Gothenburg (Table 2).
Microbiological diagnosis
Microbiological tests (i.e. bacterial culture of blood, wound or affected tissue) were taken from 97
% and 91 % of patients and microbiological diagnosis was obtained in 65 % and 73 % of the
patient population in Helsinki and Gothenburg, respectively. Staphylococci and streptococci were
the most commonly isolated pathogens in both cities although in Helsinki they were found more
often as one of the microbes in polymicrobial infections which were significantly more common in
Helsinki (34 % of patients) than in Gothenburg (13 %, p < 0.0001, Table 3). In Helsinki, more
patients (23 %) were without a microbiological diagnosis as compared to Gothenburg (12 %, p <
0.0001). Staphylococcus aureus was the most common finding in blood cultures and accounted for
46 % and 50 % of the findings in Helsinki and Gothenburg, respectively.
Antimicrobial therapy
Initial antimicrobial therapy was mainly empirical in both cities although it was significantly more
often classified as specific in Gothenburg (20 %) than in Helsinki (1.8 %, p < 0.0001). Initial
antimicrobial therapy was given intravenously in the majority of patients, in 93 % and 91 % of the
patients in Helsinki and Gothenburg, respectively. Antimicrobial agents used in initial therapy
differed significantly between cities when analysed between the main categories (broad-spectrum,
cephalosporins, penicillins, penicillins with staphylococcal effect and other; p < 0.0001, Table 5). In
total, ten different agents were used in Helsinki and 20 in Gothenburg in initial therapy (Table 5). In
Helsinki, initial antimicrobial therapy consisted almost exclusively of cephalosporins and broad-
spectrum antibiotics (carbapenems and piperacillin-tazobactam) whereas narrow-spectrum
therapies (penicillins with or without staphylococcal effect) were used more often in Gothenburg
(Table 5). Initial antimicrobial treatment covered cultured pathogens in 79 % of the patients in
Helsinki (n = 184) and 87 % of the patients in Gothenburg (n = 169, p = 0.056). Antibiotics with
definitive MRSA-coverage (vancomycin, linezolid and tigecycline) were used in initial therapy in 0.5
% and 0.4 % of the patients and in subsequent therapy in 7.4 % and 0.5 % of the patients in
Helsinki and Gothenburg, respectively.
The median overall duration of antimicrobial therapy was 29 days in Helsinki and 12 days in
Gothenburg (p < 0.0001, Table 4), and the median duration of intravenous treatment was 14 days
in Helsinki and 6.5 days in Gothenburg (p < 0.0001). There was also a difference in the number of
antibiotic changes between the cities. In Helsinki, each patient was treated in an average with 4.3
different antibiotics but in Gothenburg only 2.7 different agents per patient were used (p < 0.0001,
Table 4). Treatment was completed with the same agent that it was started with in 1.8% and 8.8%
of patients in Helsinki and Gothenburg (p = 0.0015), respectively. Initial intravenous antibiotic
treatment was modified to another intravenous drug in 55 % and 31 % of the patients (p < 0.0001)
and the median time from diagnosis to the first modification was 3 and 4 days (p = 0.0507) in
Helsinki and Gothenburg, respectively (Table 4). 77 % of the patients in Helsinki and 53 % in
Gothenburg continued with an (mainly oral) antimicrobial agent after hospital discharge (Table 5).
Clinical management and outcome
In Helsinki the patients were treated in significantly more different wards as compared to
Gothenburg (Table 4, Figure 1). In Helsinki 57 % of the patients visited two or more wards during
the hospital stay while in Gothenburg 85 % of the patients were treated in one ward only (Table 4
and Figure 1). Treatment on a surgical ward was more common in Helsinki (64 % versus 25 %, p =
0.0001) and treatment on an infectious disease ward was less common (25 % versus 48 %, p =
0.0001) as compared to Gothenburg (Table 4). The patients in Helsinki had more surgical
interventions (64 % of patients) after diagnosis of cSSSI than in Gothenburg (40 %, p < 0.0001).
The median length of hospital stay was significantly longer in Helsinki than in Gothenburg (17
versus 11 days, p < 0.0001, Table 4), but in Gothenburg, patients received more often home-
based care after discharge than in Helsinki (57 % versus 32 %, p < 0.0001).
The mean time from diagnosis to clinical stability was 4.4 days in Helsinki and 3.4 days in
Gothenburg (p = 0.0204) and treatment failure was detected in 37 % and 38 % of the patients (p =
0.8430), respectively. Within 12 months after initial discharge 16 % of the patients in Helsinki and
19 % in Gothenburg were hospitalized again due to SSSI in same the anatomical location (p =
0.3776). Mortality in Helsinki was significantly higher than in Gothenburg; 30 day mortality (5.5 %
versus 2.1 %, p = 0.0326) and 12 month mortality (16 % versus 7.5 %, p = 0.0003, respectively).
Discussion
This real-life study revealed remarkable differences in the treatment and management of cSSSI
between two centers with similar antimicrobial resistance background. In comparison to patients in
Gothenburg, patients in Helsinki were predisposed more frequently to antimicrobials with Gram-
negative coverage, had more treatment modifications, longer median duration of antimicrobial
therapy and length of hospital stay. In addition, the majority of patients in Helsinki visited more than
one ward during their hospital stay while in Gothenburg 85 % of patients were treated in one ward,
most commonly in the ward of Infectious Diseases.
Strengths and limitations of our population based retrospective study are fully discussed in the
primary publication of this material [22]. Evidently, there was some differences in the patient
populations between the two cities although we tried to apply strict criteria for patient data
collection. The baseline characteristics of the populations were quite similar (Table 1). The study
groups of both cities had a male predominance and a high number of co-morbidities but patients in
Helsinki were younger than in Gothenburg (mean age 59 versus 63 years, p = 0.0117). Statistically
significant differences were found between Helsinki and Gothenburg in the frequency of some co-
morbidities such as diabetes (50 % versus 32 %), chronic renal failure (11 % versus 2.9 %) and
respiratory disease (10 % versus 5.0 %) which were more common among patients in Helsinki but
congestive heart disease (4.6 % versus 14 %) among patients in Gothenburg, respectively. These
co-morbidities have been frequently observed in patients with cSSSI also in other studies
[14,15,23].
Many of the cSSSI related characteristics were almost identical in Helsinki and Gothenburg. In
both cities, patients were classified to have mainly cellulitis or abscess, although post-surgical
wound infections were more common in Helsinki but infected peripheral vascular disease ulcers or
infected decubitus ulcers were more prevalent in Gothenburg. No significant differences were
found between the study groups among the objective measures of disease severity like white blood
cell count at the time of diagnosis, highest C-reactive protein level, patients with septic shock or
need for blood pressure support. In both cities, the occurrence of bacteremic infections was higher
than reported in previous studies which suggests that in cSSSI blood cultures should be taken
more frequently than recommended in uncomplicated cellulitis [9,13,15].
Staphylococcus aureus (42 % versus 43 %) and streptococci (33 % versus 31 %) were the most
common pathogens both in Helsinki and in Gothenburg, respectively. The dominance of Gram-
positive bacteria among the causative agents is consistent with other studies made in patients with
cSSSI [15,23,24]. However, there were significantly more polymicrobial infections in Helsinki than
in Gothenburg and they were usually due to Gram-negative or anaerobic bacteria in conjunction
with Gram-positive bacteria. The higher prevalence of diabetes and previous hospitalization may
explain in part the higher proportion of polymicrobial infections in Helsinki, but differences in
laboratory reporting practices between countries cannot be ruled out. That is, the more abundant
reporting of species from the bacterial culture may encourage continuing with or changing to
broad-spectrum antimicrobial therapy.
Despite the similarity of the patient and disease characteristics, striking differences were observed
in clinical practices between the study centres. Based on microbiological results, Gram-negative or
anaerobic bacteria were present in the minority of patients both in Helsinki (33 %) and in
Gothenburg (18 %). Yet, 96 % of patients in Helsinki and 47 % in Gothenburg were initially treated
with antibiotics covering Gram-negative bacteria. Even after the first treatment modification, 61% of
patients in Helsinki and 33 % in Gothenburg still received Gram-negative coverage. Coverage for
Gram-negative and anaerobic bacteria in empirical treatment of SSSI is recommended by the
IDSA guidelines, mainly for infections associated with diabetic foot, peripheral vascular
insufficiency, bites, prior contact to health care and in necrotizing infections, which is consistent
with the national guidelines of Finland and Sweden [9,20,21,25]. Although many patients in both
cities belonged to these risk-groups, the majority of patients would not have needed Gram-
negative coverage according to their microbiological results. It should be noted that diabetic
foot/leg infections were rare and comprised only 15 % of patients in both cities. In the U.S., Jenkins
et al. also found similar unnecessary use of antimicrobials with Gram-negative coverage in less
severe SSSI [13]. Cephalosporin-based treatment (with Gram-negative coverage) was significantly
more common in Helsinki, whereas more penicillin-based therapies (without Gram-negative
coverage) were used in Gothenburg. This difference in antibiotic use practices might largely
explain the more common Gram-negative coverage in Helsinki. The more common cephalosporin
use in cSSSI seems to reflect the general use of antimicrobials in hospital setting. In nationwide
statistics in 2011, the use of non-penicillin beta-lactam antibiotics was five times more common in
Finland as compared to Sweden [26]. The broader antimicrobial use in Helsinki did not result in
better coverage of the cultured pathogens with the initial antimicrobial treatment, which was 87 %
in Gothenburg and 79 % in Helsinki (p = 0.056).
There were great differences in the number of different wards in which the patient was treated, in
the number of modifications in the antimicrobial treatment, and in the length of hospital stay and
antimicrobial treatment between the cities. In Helsinki, 57 % of patients were treated in more than
one ward, while in Gothenburg the majority (85 %) of patients stayed in one ward. In Helsinki,
patients were treated most frequently in the ward of Surgery, but in Gothenburg in the ward of
Infectious Diseases. To the best of our knowledge, the effect of Infectious Disease Specialist
based treatment on the outcome of patients with cSSSI has not been studied. Infectious Disease
Specialist consultation has been shown to improve the treatment of Staphylococcus aureus
bacteraemia, but in SSSI it was identified as an independent risk factor for broad-spectrum
antimicrobial therapy [27,28]. The time from diagnosis to the first modification of intravenous
antibiotic treatment to another intravenous agent was almost statistically significantly longer in
Gothenburg (median 4 days) than in Helsinki (3 days, p = 0.0507). The number of different
antibiotic courses was significantly higher in Helsinki (mean 4.3) than in Gothenburg (mean 2.7, p
< 0.0001). The frequent transfer to another ward has probably affected to the earlier and more
frequent modifications in antibiotic treatment in Helsinki.
Perhaps the most striking difference was the more than double longer total antimicrobial treatment
in Helsinki than in Gothenburg. The median duration of antimicrobial therapy in Helsinki (29 days)
also far exceeds the duration detected in previous studies and recommended in guidelines
[9,13,15,20]. The national guidelines for the treatment of (mainly uncomplicated) SSSI in Finland
and Sweden have different recommendations for total treatment durations, 14 – 21 and 10 – 14
days, respectively [20,21]. The IDSA-guideline suggests a treatment duration of 5 days if clinical
improvement has occurred, based on study of patients with uncomplicated cellulitis [9,29].
The patient population in Helsinki was more severely sick than that in Gothenburg. There were
more bacteraemic cases in Helsinki, and half of the patients in Helsinki had diabetes, as compared
to one third in Gothenburg. The 30-day mortality in Helsinki (5.5 %) was higher than in Gothenburg
(2.1 %, p = 0.0326). These mortalities fall within the range from 0.4 % to 9.0 % that has been
previously reported for cSSSI [11,14,23,30]. In comparison to Helsinki, the average time to clinical
stability was significantly shorter (3.4 versus 4.4 days) and significantly less clinical failures due to
no change or worsened clinical situation after 5 days of treatment (8.3 % versus 17 %) were
detected in Gothenburg.
In conclusion, we observed striking differences in the real-life management of cSSSI between two
Nordic cities with similar healthcare structure and prevalence of antimicrobial resistance.
Unnecessary Gram-negative antimicrobial coverage was common in both cities, although it was
more common in Helsinki. Compared to mainly Infectious Disease Specialist-guided treatment in
Gothenburg, the more frequent transfer from one ward to another in Helsinki was linked to longer
antimicrobial therapy and hospital stay and to more frequent changes in antimicrobial treatment.
This study suggests that infectious disease specialist-guided therapy and avoidance of transfers
between wards may have a role in the optimizing of antimicrobial treatment.
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Male Gender 140 (63.9%) 140 (58.1%) 0.2145 [a]
Age Mean (sd) 58.6 (17.5) 62.9 (18.5)
Median 60.0 63.0
Q1, Q3 44.0, 74.0 49.0, 77.0
Min, Max 19, 93 18, 98 0.0117 [b]
Number of co-morbidities 0 59 (26.9%) 53 (22.0%)
1 83 (37.9%) 90 (37.3%)
2 49 (22.4%) 71 (29.5%)
≥3 28 (12.8%) 27 (11.2%) 0.8614 [c]
AIDS / HIV infection 6 (2.7%) 1 (0.4%) 0.0631 [d]
Any disease with immune system impairment 5 (2.3%) 9 (3.7%) 0.2807 [d]
Cancer / Malignancy 14 (6.4%) 22 (9.1%) 0.4028 [d]
Chronic renal failure 25 (11.4%) 7 (2.9%) 0.0004 [d]
Congestive heart disease 10 (4.6%) 33 (13.7%) 0.0077 [d]
Diabetes 109 (49.8%) 78 (32.4%) <0.0001 [d]
Liver disease 11 (5.0%) 12 (5.0%) 0.7405 [d]
Other relevant disease 30 (13.7%) 37 (15.4%) 0.5832 [d]
Other renal disease 2 (0.9%) 6 (2.5%) 0.2902 [d]
Respiratory disease 22 (10.0%) 12 (5.0%) 0.0273 [d]
Hospitalization within 3 months previous to the index visit 51 (23.3%) 33 (13.7%) 0.0235 [d]
Invasive surgery within 3 months previous to the index visit 41 (18.7%) 30 (12.4%) 0.1667 [d]
Treatment with antibiotic before diagnosis of cSSSI 53 (24.2%) 82 (34.0%) 0.0293 [d]
[a] P-value for Fisher's exact test for association between cities and the variable
[b] P-value for difference between cities (t-test, pooled variances)
[c] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (row mean scores differ))
[d] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (general association))
Table 1. Demographics and characteristics of patients with complicated skin and skin structure






Abscess 93 (42.5%) 90 (37.3%) 0.8536 [b]
Bite 1 (0.5%) 1 (0.4%) 0.9689 [b]
Burn
Cellulitis / fasciitis [a] 95 (43.4%) 98 (40.7%) 0.4417 [b]
Decubitus ulcer (pressure ulcer) 1 (0.5%) 13 (5.4%) 0.0022 [b]
Diabetic foot ulcer 24 (11.0%) 24 (10.0%) 0.7022 [b]
Diabetic leg ulcer 8 (3.7%) 13 (5.4%) 0.3976 [b]
Lesion: Other 2 (0.8%) 0.1496 [b]
Lesion: Unknown 4 (1.7%) 0.1475 [b]
Peripheral vascular disease ulcer 14 (6.4%) 39 (16.2%) 0.0208 [b]
Post-surgical wound 50 (22.8%) 29 (12.0%) 0.0026 [b]
Post-traumatic wound 22 (10.0%) 28 (11.6%) 0.5750 [b]
Number of days between symptoms start and
diagnosis
< 2 days 87 (39.7%) 43 (17.8%)
2-7 days 109 (49.8%) 121 (50.2%)
> 7 days 23 (10.5%) 67 (27.8%)
Missing 10 (4.1%) <0.0001 [c]
White blood cell count at the time of diagnosis < 4000/mm3 3 (1.4%) 2 (0.8%) 0.6083 [b]
> 10000/mm3 193 (88.1%) 202 (83.8%) 0.1864 [b]
Highest CRP per patient No. of obs. 219 232
Mean (sd) 229.1 (116.7) 216.0 (140.0)
Median 221.0 200.0
Q1, Q3 143.0, 303.0 110.0, 300.0
Min, Max 17, 681 5, 640 0.4854 [d]
Septic shock 2 (0.9%) 3 (1.2%) 0.8127 [b]
Blood pressure support 54 (24.7%) 76 (31.5%) 0.0514 [b]
[a] Patients not having abscess, diabetic foot ulcer, diabetic leg ulcer or peripheral vascular disease ulcer
[b] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (general association))
[c] P-value for difference between cities, controlling for age (Wilcoxon rank sum test stratified by agegroup)
[d] P-value for difference between cities, controlling for age (2-way ANOVA)
Table 2. Disease characteristics of patients with complicated skin and skin structure infection in
Helsinki and Gothenburg.





Monomicrobial infections 69 (32.4%) 148 (67.6%) <0.0001
Staphylococci 32 (15%) 74 (33.8%) <0.0001
    Methicillin Sensitive S. aureus (MSSA) 27 (12.7%) 62 (28.3%) 0.0006
    Methicillin Resistant S. aureus (MRSA) 2 (0.9%) 1 (0.5%) 0.4631
    Coagulase-negative staphylococci 3 (1.4%) 11 (5%) 0.0233
Streptococci 23 (10.8%) 46 (21%) 0.0025
    Streptococcus pyogenes 13 (6.1%) 27 (12.3%) 0.0182
    Streptococcus agalactiae 2 (0.9%) 1 (0.5%) 0.4357
    Beta-hemolytic Streptococci 8 (3.8%) 16 (7.3%) 0.1032
    Streptococcus pneumoniae 0 2 (0.9%) 0.1154
Enterococci 0 2 (0.9%) 0.1468
Enterobacteriacae 7 (3.3%) 7 (3.2%) 0.5397
Pseudomonas 2 (0.9%) 2 (0.9%) 0.9390
Other gramnegative bacteria 1 (0.5%) 3 (1.4%) 0.6507
Anaerobic bacteria 2 (0.9%) 2 (0.9%) 0.8329
Other microorganism 2 (0.9%) 12 (5.5%) 0.0046
Polymicrobial infections 73 (34.3%) 29 (13.2%) <0.0001
    Only Gram-positive bacteria 17 (8%) 16 (7.3%) 0.7344
    Only Gram-negative bacteria 3 (1.4%) 1 (0.5%) 0.2567
    Mixed 53 (24.9%) 12 (5.5%) <0.0001
Negative 48 (22.5%) 27 (12.3%) 0.0029
Missing [b] 23 (10.8%) 15 (6.8%)
[a] Result from first test where blood culture and/or swab/needle aspiration and culture exist
[b] Diagnosis unknown, or missing dates so first test can't be defined
[c] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (general association))







Length of hospital stay, days No. of obs. 193 225
Mean (sd) 29.0 (41.6) 15.2 (22.1)
Median 17.0 11.0
Q1, Q3 8.0, 32.0 6.0, 18.0
Min, Max 2, 298 1, 278 <0.0001 [d]
Number of wards the patient visited
during hospital stay [a]
No. of obs. 219 232
1 94 (42.9%) 196 (84.5%)
2 68 (31.1%) 32 (13.8%)
3 26 (11.9%) 4 (1.7%)
≥4 31 (14.2%) <0.0001 [e]
Wards the patient visited during hospital
stay
Intensive Care Unit (ICU) 41 (18.7%) 32 (13.3%) 0.2675 [f]
Emergency Medicine Room (EMR) 25 (11.4%) 9 (3.7%) 0.0036 [f]
Medicine [b] 110 (50.2%) 81 (33.6%) 0.0001 [f]
Surgery 140 (63.9%) 61 (25.3%) 0.0001 [f]
Infection 54 (24.7%) 116 (48.1%) 0.0001 [f]
Other [c] 19 (8.7%) 4 (1.7%) 0.0009 [f]
Number of different antibiotic therapy
courses
No. of obs. 219 238
Mean (sd) 4.3 (2.6) 2.7 (1.1)
Median 4.0 3.0
Q1, Q3 2.0, 5.0 2.0, 3.0
Min, Max 1, 18 1, 8 <0.0001 [d]
Overall treatment duration, days No. of obs. 219 240
Mean (sd) 42.8 (59.9) 17.3 (28.7)
Median 29.0 12.0
Q1, Q3 16.0, 44.0 6.0, 20.0
Min, Max 1, 606 1, 372 <0.0001 [d]
Any detected insufficient response or
treatment failure [g]
Unplanned surgical drainage 53 (24.2%) 72 (29.9%) 0.1195 [f]
Treatment failure registered into
patient records by the treating
physician
14 (6.4%) 8 (3.3%) 0.1030 [f]
No change or worsened clinical
situation after 5 days of treatment
37 (16.9%) 20 (8.3%) 0.0052 [f]
Other 1 (0.5%) 3 (1.2%) 0.5137 [f]
No 137 (62.6%) 149 (61.8%) 0.8430 [f]
[a] Can include same ward several times, patients can visit one ward more than once
[b] Includes Helsinki City Hospital
[c] Dermatology, Otorhinolaryngology, Obstetrics and Gynecology, Oncology and Pulmonology
[d] P-value for difference between cities, controlling for age (2-way ANOVA)
[e] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (row mean scores differ))
[f] P-value for association between cities and the variable, controlling for age (Cochran-Mantel-
Haenszel (general association))
[g] A patient can have more than one detected insufficient response or treatment failure
Table 4. Clinical management and use of resources in patients with complicated skin and skin
structure infection in Helsinki and Gothenburg.
Table 5. Antimicrobial treatment of patients with complicated skin and skin structure infection in
Helsinki and Gothenburg.
Antibiotic agent Initial therapy Subsequent therapy Discharge agents












Broad-spectrum 58 (26.5%) 29 (12.1%) 46 (21.3%) 21 (9.7%) 1 (1.0%)
   Carbapenem 51 (23.3%) 7 (2.9%) 38 (17.6%) 11 (5.1%)
   Piperacillin-Tazobactam 7 (3.2%) 22 (9.2%) 8 (3.7%) 10 (4.6%) 1 (1.0%)
Cephalosporins 151 (68.9%) 73 (30.5%) 65 (30.1%) 33 (15.3%) 80 (58.4%) 9 (8.8%)
   Cefalexin 2 (0.9%) 40 (18.5%) 79 (57.7%)
   Cefadroxil 1 (0.4%) 9 (4.2%) 8 (7.8%)
   Cefuroxime 139 (63.5%) 17 (7.1%) 16 (7.4%) 1 (0.5%)
   Ceftriaxone 10 (4.6%) 8 (3.7%)
   Cefotaxim 55 (23.0%) 23 (10.6%) 1 (1.0%)
   Ceftazidim 1 (0.5%)
   Cefazolin 1 (0.7%)
Penicillins with staphylococcal effect 52 (21.8%) 9 (4.2%) 49 (22.7%) 8 (5.8%) 37 (36.3%)
   Cloxacillin 41 (17.2%) 7 (3.2%) 13 (6.0%)
   Flucloxacillin 10 (4.2%) 34 (15.7%) 33 (32.4%)
   Dicloxacillin 1 (0.5%) 1 (1.0%)
   Betalactamase-stable Penicillin 1 (0.4%)
   Amoxicillin-Clavulanic Acid 2 (0.9%) 1 (0.5%) 8 (5.8%) 3 (2.9%)
Penicillins 2 (0.9%) 51 (21.3%) 8 (3.7%) 29 (13.4%) 5 (3.6%) 18 (17.6%)
   Benzylpenicillin 2 (0.9%) 49 (20.5%) 4 (1.9%) 13 (6.0%) 4 (3.9%)
   Fenoxymethylpenicillin 1 (0.4%) 3 (1.4%) 14 (6.5%) 3 (2.2%) 12 (11.8%)
   Ampicillin 1 (0.5%)
   Amoxicillin 1 (0.4%) 2 (0.9%) 2 (1.5%) 2 (2.0%)
Other 8 (3.7%) 34 (14.2%) 88 (40.7%) 84 (38.9%) 86 (62.8%) 48 (47.1%)
   Clindamycin 4 (1.8%) 18 (7.5%) 13 (6.0%) 50 (23.1%) 25 (18.3%) 34 (33.3%)
   Fluoroquinolone 2 (0.9%) 4 (1.7%) 16 (7.4%) 10 (4.6%) 28 (20.4%) 7 (6.9%)
   Metronidazole 3 (1.3%) 36 (16.7%) 15 (6.9%) 17 (12.4%) 4 (3.9%)
   Vancomycin 1 (0.4%) 14 (6.5%) 1 (0.5%)
   Linezolid 1 (0.5%) 1 (0.5%) 3 (2.2%)
   Tigecyclin 1 (0.5%)
   Co-trimoxazole 1 (0.4%) 3 (1.4%) 2 (1.5%)
   Tobramycin 3 (1.3%) 3 (1.4%)
   Doxycyklin 2 (0.8%) 1 (0.5%) 2 (2.0%)
   Fusidic Acid 1 (0.4%) 1 (0.7%) 1 (1.0%)
   Netilmycin 1 (0.5%)
   Fluconazole 2 (0.9%) 1 (0.5%) 5 (3.7%)
   Anidulafungin 1 (0.5%)
   Rifampicin 1 (0.7%)
Unknown 1 (0.5%) 1 (0.4%) 3 (1.4%) 4 (2.9%)
Figure 1. The flow of patients with complicated skin and skin
structure infections between wards during their hospital stay in
Helsinki (left) and in Gothenburg (right). The thickness of arrow
indicates the number of patient transfers between the wards. The
arrows outside the circle pointing inside indicate the first ward the
patient entered and the outward arrow the discharging ward. EMR =
Emergency Medicine Room.
